PE20240811A1 - Metodo para tratar la endometriosis y proporcionar una anticoncepcion eficaz - Google Patents
Metodo para tratar la endometriosis y proporcionar una anticoncepcion eficazInfo
- Publication number
- PE20240811A1 PE20240811A1 PE2024000240A PE2024000240A PE20240811A1 PE 20240811 A1 PE20240811 A1 PE 20240811A1 PE 2024000240 A PE2024000240 A PE 2024000240A PE 2024000240 A PE2024000240 A PE 2024000240A PE 20240811 A1 PE20240811 A1 PE 20240811A1
- Authority
- PE
- Peru
- Prior art keywords
- weight
- drospirenone
- endometriosis
- provide effective
- treat endometriosis
- Prior art date
Links
- 201000009273 Endometriosis Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 abstract 3
- METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 abstract 3
- 229960004845 drospirenone Drugs 0.000 abstract 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract 2
- 239000003433 contraceptive agent Substances 0.000 abstract 2
- 230000002254 contraceptive effect Effects 0.000 abstract 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 abstract 1
- 201000000736 Amenorrhea Diseases 0.000 abstract 1
- 206010001928 Amenorrhoea Diseases 0.000 abstract 1
- 208000005171 Dysmenorrhea Diseases 0.000 abstract 1
- 206010013935 Dysmenorrhoea Diseases 0.000 abstract 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- 208000000450 Pelvic Pain Diseases 0.000 abstract 1
- 231100000540 amenorrhea Toxicity 0.000 abstract 1
- 229960004977 anhydrous lactose Drugs 0.000 abstract 1
- 230000002051 biphasic effect Effects 0.000 abstract 1
- 235000019359 magnesium stearate Nutrition 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 238000004806 packaging method and process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000377 silicon dioxide Substances 0.000 abstract 1
- 235000012239 silicon dioxide Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pregnancy & Childbirth (AREA)
Abstract
La presente invencion refiere a la drospirenona para su uso en un metodo para tratar la endometriosis, el dolor pelvico asociado a endometriosis (DPAE) y/o la dismenorrea, el cual comprende administrar en un regimen bifasico desde el dia 1 al 24 una cantidad diaria de 4,0 mg y desde el dia 25 al 28 una cantidad de 2,8 mg. Asimismo, la presente refiere al uso de la drospirenona como anticonceptivo y para inducir amenorrea; a un kit anticonceptivo que presenta una o mas unidades de envasado, en donde la primera unidad comprende 24 unidades de dosificacion diaria y la segunda unidad comprende 4 unidades de dosificacion diaria; y a una composicion farmaceutica que comprende drospirenona de 1 % al 10 % en peso, celulosa microcristalina de 50 % al 65 % en peso, lactosa anhidra de 25 % al 35 % en peso, dioxido de silicio de 0,2 % al 6 % en peso y estearato de magnesio de 0,2 % al 0,6 % en peso.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21382757.9A EP4134082A1 (en) | 2021-08-12 | 2021-08-12 | Method for treating endometriosis and providing effective contraception |
| PCT/EP2022/072511 WO2023017109A1 (en) | 2021-08-12 | 2022-08-11 | Method for treating endometriosis and providing effective contraception |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20240811A1 true PE20240811A1 (es) | 2024-04-18 |
Family
ID=77358188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2024000240A PE20240811A1 (es) | 2021-08-12 | 2022-08-11 | Metodo para tratar la endometriosis y proporcionar una anticoncepcion eficaz |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP4134082A1 (es) |
| KR (1) | KR20240047421A (es) |
| CN (1) | CN118076358A (es) |
| AR (1) | AR126766A1 (es) |
| AU (1) | AU2022327756A1 (es) |
| CA (1) | CA3228483A1 (es) |
| CO (1) | CO2024001947A2 (es) |
| IL (1) | IL310634A (es) |
| PE (1) | PE20240811A1 (es) |
| TW (1) | TW202320801A (es) |
| WO (1) | WO2023017109A1 (es) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2652761C2 (de) | 1976-11-16 | 1985-11-21 | Schering AG, 1000 Berlin und 4709 Bergkamen | 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel |
| DE19633685C1 (de) | 1996-08-12 | 1997-10-09 | Schering Ag | Verfahren zur Herstellung von Drospirenon (6beta,7beta;15 beta,16beta-Dimethyl-en-3-oxo-17alpha-pregn-4-en-21,17-carbolacton, DRSP) sowie 7alpha-(3-Hydroxy-1-propyl)-6beta,7beta;15beta, 16beta-dimethylen-5beta-androstan-3beta,5,17beta-triol (ZK 92836) und 6beta,7beta;15beta,16beta-dimethylen-5beta-hydroxy-3-oxo-17alpha-androstan-21,17-carbolacton (90965) als Zwischenprodukte des Verfahrens |
| ITMI20042338A1 (it) | 2004-12-06 | 2005-03-06 | Ind Chimica Srl | Processo per la preparazione di drospirenone |
| US10849857B2 (en) * | 2010-07-28 | 2020-12-01 | Laboratorios Leon Farma Sa | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
| AR081670A1 (es) | 2010-06-29 | 2012-10-10 | Leon Farma Sa Lab | Composicion farmaceutica que comprende drospirenona y kit anticonceptivo |
| ES2970532T3 (es) | 2015-06-23 | 2024-05-29 | Laboratorios Leon Farma Sa | Anticonceptivo basado en drospirenona para una paciente que presenta exceso de peso |
| KR20220144885A (ko) * | 2016-08-05 | 2022-10-27 | 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 | 월경통 및 생리통의 관리방법 |
| JP2018083806A (ja) * | 2016-11-11 | 2018-05-31 | 持田製薬株式会社 | 月経困難症治療用組成物 |
-
2021
- 2021-08-12 EP EP21382757.9A patent/EP4134082A1/en not_active Withdrawn
-
2022
- 2022-08-11 AR ARP220102164A patent/AR126766A1/es unknown
- 2022-08-11 CN CN202280066560.XA patent/CN118076358A/zh active Pending
- 2022-08-11 CA CA3228483A patent/CA3228483A1/en active Pending
- 2022-08-11 PE PE2024000240A patent/PE20240811A1/es unknown
- 2022-08-11 WO PCT/EP2022/072511 patent/WO2023017109A1/en active Application Filing
- 2022-08-11 AU AU2022327756A patent/AU2022327756A1/en active Pending
- 2022-08-11 IL IL310634A patent/IL310634A/en unknown
- 2022-08-11 TW TW111130168A patent/TW202320801A/zh unknown
- 2022-08-11 KR KR1020247008289A patent/KR20240047421A/ko unknown
-
2024
- 2024-02-22 CO CONC2024/0001947A patent/CO2024001947A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022327756A1 (en) | 2024-03-14 |
| IL310634A (en) | 2024-04-01 |
| AR126766A1 (es) | 2023-11-08 |
| KR20240047421A (ko) | 2024-04-12 |
| CO2024001947A2 (es) | 2024-03-07 |
| CN118076358A (zh) | 2024-05-24 |
| TW202320801A (zh) | 2023-06-01 |
| EP4134082A1 (en) | 2023-02-15 |
| WO2023017109A1 (en) | 2023-02-16 |
| CA3228483A1 (en) | 2024-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2693085T1 (es) | Uso de estriol en bajas dosis | |
| Friend et al. | Multipurpose prevention technologies: products in development | |
| PE20211588A1 (es) | Compuestos y sus usos para aliviar sintomas asociados a la menopausia | |
| EA200900491A1 (ru) | Применение эстрадиола валерата или 17в-эстрадиола в комбинации с диеногестом для перорального лечения для поддержания и/или повышения полового влечения у особи женского пола | |
| AR057060A1 (es) | Composiciones de tanaproget que contienen etinil estradiol | |
| NO20080824L (no) | Oral prevensjon med trimegeston | |
| RS53876B1 (en) | PARENTERAL PHARMACEUTICAL FORM, WHICH RELEASES AROMATASE AND GESTAGEN BLOCKERS, FOR THE TREATMENT OF ENDOMETRIOSIS | |
| ECSP078001A (es) | Composición farmacéutica que contienen gestágenos y/o estrógenos y 5-metil-(6s)-tetrahidrofolato | |
| CO2021000174A2 (es) | Composiciones tópicas para el alivio del dolor | |
| PE20060275A1 (es) | Composicion farmaceutica que contiene progestina y estrogeno para el tratamiento de trastorno disforico premenstrual | |
| HN2008000621A (es) | Metodo para la anticopcepcion hormonal preventiva bajo demanda | |
| RU2007148080A (ru) | Составы и способы для лечения симптомов, связанных с циклом | |
| AR082998A1 (es) | Asociacion farmaceutica para tratar y/o prevenir mioma y/o endometriosis, uso de resveratrol y progestogeno, composicion farmaceutica para tratamiento y/o prevencion de mioma y/o endometriosis, medicamento para tratamiento y/o prevencion de mioma y/o endometriosis, kit y metodo para tratamiento y/o prevencion de mioma y/o endometriosis | |
| PE20080273A1 (es) | Composicion farmaceutica que contiene un progestageno, un estrogeno y un acido tetrahidrofolico | |
| ECSP077131A (es) | Regímenes y los juegos de anticonceptivos del antagonista del receptor de progesterona | |
| HRP20240121T1 (hr) | Kontracepcija na bazi drospirenona za pacijenticu s viškom tjelesne težine | |
| CR8010A (es) | Regimenes de contraceptivos transdermicos extendidos | |
| PE20240811A1 (es) | Metodo para tratar la endometriosis y proporcionar una anticoncepcion eficaz | |
| Farajkhoda et al. | Assessment of two emergency contraceptive regimens in Iran: levonorgestrel versus the Yuzpe | |
| HRP20090256T1 (en) | Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method | |
| PE20090805A1 (es) | COMBINACION DE DROSPIRENONA Y 17ß-ESTRADIOL COMO CONTRACEPTIVO ORAL | |
| BRPI0606724A2 (pt) | preparação farmacêutica para contracepção | |
| TR201714149A2 (tr) | Ulipristal asetat içeren bir tablet formülasyonu. | |
| Dubrovina | Topical issues in combined oral contraceptives usage | |
| Kavitha et al. | Dose Dependent Amitriptyline Induced Sexual Dysfunction in a Migraine Patient |